Carotid stenosis
Drug research and approvals for carotid stenosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 62 studies of carotid stenosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 62
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Evalutation of Ocular Symptoms in Asymptomatic Carotid Artery StenosisNCT07949006 · Not reported · University of Bologna · starts Jan 1, 2027
- PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)NCT07916883 · Not reported · Washington University School of Medicine · starts Nov 18, 2026
- Perioperative GFAP and Neurological Complications After Carotid EndarterectomyNCT07843979 · Not reported · Filiz Ata · starts Dec 15, 2025
- Photon-Counting CT Versus Conventional CT for Carotid Plaque Assessment in Patients With Carotid Artery StenosisNCT07762664 · Not reported · Chinese PLA General Hospital · starts Jan 7, 2026
- Comparison Between Non-contrast Magnetic Resonance Angiography and Carotid Doppler in Cerebrovascular StrokeNCT07756775 · Not reported · Sohag University · starts Jul 20, 2026
- Whole-life Investigation of Lishui LongevityNCT07592962 · Not reported · The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · starts May 18, 2026
- Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid PlaqueNCT07586540 · Phase 3 · Middle East North Africa Stroke and Interventional Neurotherapies Organization · starts Jan 6, 2026
- Evaluation of Balloon Guide Catheter as Proximal Protection During Carotid Artery Stenting (EMBO-PROTECT)NCT07576790 · Not applicable · Instituto de Investigación Marqués de Valdecilla · starts Jul 1, 2026
- Clinical Impact of Using IMPROVE to Select Patients for Carotid RevascularisationNCT07556887 · Not applicable · Maastricht University Medical Center · starts Mar 31, 2026
Phase 3 3
- ClopidogrelPurinergic receptor P2Y12 antagonist
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- TiclopidinePurinergic receptor P2Y12 antagonist
Phase 2 8
- AspirinCyclooxygenase inhibitor
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- DipyridamoleEquilibrative nucleoside transporter 1 inhibitor
- LovastatinHMG-CoA reductase inhibitor
- TerazosinAdrenergic receptor alpha-1 antagonist
- MinocyclineBacterial 70S ribosome inhibitor
- FasudilRho-associated protein kinase inhibitor
- DPA-714
Phase 1 or earlier 1
- AbciximabIntegrin alpha-IIb/beta-3 inhibitor
How its trials ended
308 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 50 whose ending is known, 34% met their primary endpoint, 4% missed it and 62% stopped early.
- Completed, result not reported11939%
- Ongoing7324%
- Status unknown6621%
- Met its primary endpoint176%
- Stopped: other or unclear134%
- Stopped: enrollment or feasibility93%
- Stopped: sponsor or business decision62%
- Stopped: lack of efficacy31%
- Missed its primary endpoint21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA